305 related articles for article (PubMed ID: 9425914)
1. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
[TBL] [Abstract][Full Text] [Related]
2. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.
Saló J; Ginès A; Quer JC; Fernández-Esparrach G; Guevara M; Ginès P; Bataller R; Planas R; Jiménez W; Arroyo V; Rodés J
J Hepatol; 1996 Dec; 25(6):916-23. PubMed ID: 9007721
[TBL] [Abstract][Full Text] [Related]
3. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Gülberg V; Bilzer M; Gerbes AL
Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
[TBL] [Abstract][Full Text] [Related]
5. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
6. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin].
Gülberg V; Luppa P; Pauletzki J; Paumgartner G; Gerbes AL
Z Gastroenterol; 1998 Dec; 36(12):1053-8. PubMed ID: 10025057
[TBL] [Abstract][Full Text] [Related]
7. [Physiopathology of refractory ascites and the hepatorenal syndrome].
Arroyo V
Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
[No Abstract] [Full Text] [Related]
8. New treatments of hepatorenal syndrome.
Arroyo V; Terra C; Ginès P
Semin Liver Dis; 2006 Aug; 26(3):254-64. PubMed ID: 16850375
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of hepatorenal syndrome].
Walter E
Praxis (Bern 1994); 1997 Jan; 86(4):102-3. PubMed ID: 9064719
[TBL] [Abstract][Full Text] [Related]
11. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
14. [Hepatorenal syndrome].
Mijac D; Kezić A; Stojimirović B
Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Saner F; Kavuk I; Lang H; Biglarnia R; Frühauf NR; Schäfers RF; Malagó M; Broelsch CE
Eur J Med Res; 2004 Feb; 9(2):78-82. PubMed ID: 15090293
[TBL] [Abstract][Full Text] [Related]
16. Prolonged infusion of ornithine plus dopamine in the treatment of the hepatorenal syndrome: a breakthrough?
Conn HO
Am J Gastroenterol; 2000 Dec; 95(12):3645-6. PubMed ID: 11151911
[No Abstract] [Full Text] [Related]
17. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.
Fernández J; Monteagudo J; Bargallo X; Jiménez W; Bosch J; Arroyo V; Navasa M
Hepatology; 2005 Sep; 42(3):627-34. PubMed ID: 16108036
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of hepatorenal syndrome.
Ginès P
Baillieres Best Pract Res Clin Gastroenterol; 2000 Dec; 14(6):945-57. PubMed ID: 11139348
[TBL] [Abstract][Full Text] [Related]
19. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?
Gülberg V; Gerbes AL
Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Uriz J; Ginès P; Cárdenas A; Sort P; Jiménez W; Salmerón JM; Bataller R; Mas A; Navasa M; Arroyo V; Rodés J
J Hepatol; 2000 Jul; 33(1):43-8. PubMed ID: 10905585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
